AstraZeneca: Externally Sponsored Scientific Research (ESR) – Rare Diseases Focus
AstraZeneca’s rare-disease partners (Alexion) welcome investigator-initiated proposals on haematologic, metabolic, and immunologic orphan conditions. Research areas range from complement-mediated disorders to ultra-rare enzymopathies, with emphasis on translational models and natural-history studies.
Eligibility Criteria:
-
External investigators at specialised rare-disease centres.
-
Protocols must involve Alexion-licensed assets or unbranded exploratory work.
-
Ethical and regulatory approvals required before submission.
Funding Details:
-
Support Type: Drug-only supply, assay development, registry access, and translational-lab collaborations.
-
Submission Process: Proposals submitted via the Alexion iEnvision portal.
Deadline:
Ongoing intake; portal registration required.
Where to Go for Further Information:
Register in iEnvision.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023